Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week Open-Label Non-Interventional Evaluation of Atacand® (Candesartan) Efficacy, Tolerability, Compliance and Treatment Satisfaction in Patients With Arterial Hypertension

NCT00837720 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00837720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00837720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week Open-Label Non-Interventional Evaluation of Atacand® (Candesartan) Efficacy, Tolerability, Compliance and Treatment Satisfaction in Patients With Arterial Hypertension
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
March 31, 2006
Completion date
June 30, 2007
Enrollment
750 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension